Effect of hydrocortisone on the 28-day mortality of patients with septic acute kidney injury

Differential effects of acute and chronic hydrocortisone treatment on pyroptosis

Pyroptosis is a programmed and inflammation-inducing cell death that occurs predominantly in macrophages. It is characterized by the inflammasome-mediated activation of caspase-1, leading to cell lysis. During pyroptosis, pro-inflammatory mediators such as IL-1β are released extracellularly to further recruit and activate other immune cells. Thus, pyroptosis plays a crucial role in the prevention of the spread of pathogens. The clinically applied synthetic glucocorticoid, hydrocortisone (HC), has strong immunoregulatory properties. It may act as an immunosuppressive agent by negatively regulating pro-inflammatory gene transcription but has also shown immune-sensitizing properties. The conditions that determine the immunosuppressive or immune-sensitizing actions of HC during an infection are not fully clear. We hypothesized that the outcome may differ depending on the onset and duration of its administration. Therefore, we investigated the impact of acute (treatment upon infection) and chronic (24 h pre-treatment before infection) HC treatment on pyroptosis induction and execution in THP-1 macrophage-like cells. The focus was on pyroptosis-associated signaling pathways, inflammasome assembly and activation, IL-1β, and cell death. Physiological HC concentration and HC deprivation were used as controls. Compared to the physiological concentration, cells displayed augmented inflammasome activation and IL-1β release following acute HC treatment. Conversely, the whole pyroptosis machinery was suppressed by chronic HC administration. These in vitro investigations demonstrate pro-inflammatory actions of acute HC exposure and the immunosuppressive effects of chronic treatment. These differential effects on pyroptosis emphasize the importance of individualized HC medication in patients upon infection, and suggest the inclusion of IL-1β as a marker for current immune capacities.

Correlation Analysis of Blood Glucose Level with Inflammatory Response and Immune Indicators in Patients with Sepsis

Objective

To analyze the correlation of blood glucose level with inflammatory response and immune indicators in patients with sepsis.

Methods

Between February 2019 and February 2021, 30 sepsis patients and 30 sepsis patients complicated with diabetes mellitus admitted to our hospital were recruited and assigned to either the experimental group (sepsis patients) or the observation group (sepsis patients with diabetes mellitus). Another 30 healthy subjects in the same period were included as the control group. The levels of IL-6, TNF-α, IL-1β, CD4+, and CD8+ in the three groups of patients were compared to analyze the correlation of blood glucose levels with inflammatory response and immune indicators in patients with sepsis. The difference of counting data was analyzed using the chi-square test, and the difference of measurement data was analyzed using the t-test.

Results

The control group showed the lowest levels of IL-6 at 14.32 ± 4.98 pg/ml, followed by 18.33 ± 3.27 pg/ml in the experimental group and then 22.64 ± 5.16 pg/ml in the observation group (P < 0.05). The levels of other inflammatory factors including TNF-α and IL-1β were the lowest in the control group, followed by the experimental group, and then the observation group (P < 0.05). The lowest immune function indicator CD4+ and CD8+ levels were found in the observation group, followed by the experimental group, and then the control group (P < 0.05). The blood glucose level of patients with sepsis was positively correlated with the levels of IL-6, TNF-α, and IL-1β and was negatively correlated with the levels of CD4+/CD8+. The higher the blood glucose, the lower the number of immune cells.

Conclusion

The blood glucose level of patients with sepsis is positively correlated with inflammatory response and negatively with immune indicators. An increased blood sugar level is associated with aggravated inflammatory responses and a decreased number of immune cells, which provides a reference for the disease severity assessment and treatment of patients with sepsis.

Divergence between serum creatine and cystatin C in estimating glomerular filtration rate of critically ill COVID-19 patients

Background

The clinical use of serum creatine (sCr) and cystatin C (CysC) in kidney function evaluation of critically ill patients has been in continuous discussion. The difference between estimated glomerular filtration rate calculated by sCr (eGFRcr) and CysC (eGFRcysc) of critically ill COVID-19 patients were investigated in this study.

Methods

This is a retrospective, single-center study of critically ill patients with COVID-19 admitted in intensive care unit (ICU) at Wuhan, China. Control cases were moderate COVID-19 patients matched in age and sex at a ratio of 1:1. The eGFRcr and eGFRcysc were compared. The association between eGFR and death were analyzed in critically ill cases. The potential factors influencing the divergence between eGFRcr and eGFRcysc were explored.

Results

A total of 76 critically ill COVID-19 patients were concluded. The mean age was 64.5 ± 9.3 years. The eGFRcr (85.45 (IQR 60.58–99.23) ml/min/1.73m²) were much higher than eGFRcysc (60.6 (IQR 34.75–79.06) ml/min/1.73m²) at ICU admission. About 50 % of them showed eGFRcysc < 60 ml/min/1.73 m² while 25% showed eGFRcr < 60 ml/min/1.73 m² (χ² = 10.133, p = 0.001). This divergence was not observed in moderate group. The potential factors influencing the divergence included serum interleukin-6 (IL-6), tumor necrosis factor (TNF-α) level as well as APACHEII, SOFA scores. Reduced eGFRcr (<60 mL/min/1.73 m²) was associated with death (HR = 1.939, 95%CI 1.078–3.489, p = 0.027).

Conclusions

The eGFRcr was generally higher than eGFRcysc in critically ill COVID-19 cases with severe inflammatory state. The divergence might be affected by inflammatory condition and illness severity. Reduced eGFRcr predicted in-hospital death. In these patients, we advocate for caution when using eGFRcysc.

Discrimination of Chronic Kidney Disease and Diabetic Nephropathy and Analysis of Their Related Influencing Factors

PURPOSE

Clinically there are not many clinical indicators to differentiate diabetic kidney disease (DKD) and chronic kidney disease (CKD). Data from laboratory inspections on admission of clinical patients were used to complete the relationship and discrimination analysis of the two diseases.

PATIENTS AND METHODS

All subjects were taken from the Department of Nephrology of the Second Hospital of Jilin University from January 2019 to September 2020 with clinical diagnosis of CKD or diabetic nephropathy and no other diseases. After querying the hospital's medical record system, the basic demographic information was obtained, and data on cardiovascular, metabolism, renal function, blood function, and other relevant indicators were extracted as well. IBM SPSS 24.0 software was used for data collation and analysis.

RESULTS

A total of 1726 inpatients (986 males and 740 females) over 18 years old were included, 1407 were CKD patients, 319 were DKD patients. Female accounted for 55.4% in CKD patients, 64.6% in DKD patients. Compared to men, women may be more susceptible to DKD (OR=2.234). DKD patients were more likely to be have higher DP, GLU, eGFR, TCHO, and abnormal TVU (OR=1.746, 3.404, 1.107, 3.004, 14.03) while VB₁₂ was the relative risk factor for CKD; thus, low VB₁₂ level is more likely to happen in CKD patients (OR=0.054, OR95%CI: 0.005-0.552, P=0.014) compared with DKD patients. The stepwise discriminant analysis was completed, only 11 of the 34 variables had discriminative significance. The discriminant score (DS) was set to explore its test efficiency of DKD prediction by drawing ROC curve. Discriminant formula used for CKD and DN identification was given in the study.

CONCLUSION

Female, higher DP, fasting blood GLU and TCHO level seemed to be more indicative for DKD, while lower eGFR level and VB₁₂ deficiency were more likely to point to CKD. Doctors can refer to the discriminant formula to assist in the differential diagnosis of the two diseases after completing the detection of DP, fasting blood GLU, Cys-C, eGFR, TVU, TCHO, FA, VB12, CK, and CK-Mb.